Company intelligence / Profile preview

Vaxcel

Norcross, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Vaxcel was a biopharmaceutical company focused on the development of vaccine delivery systems and specialized drug delivery technologies. The company's core platform utilized microsphere technology designed to enhance the immune response to vaccines and improve the delivery of therapeutic agents. Vaxcel's research primarily targeted infectious diseases and oncology, aiming to create more effective and stable vaccine formulations. The company was eventually acquired by VaxGen, which sought to integrate Vaxcel's delivery capabilities into its own vaccine development programs.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineDrug delivery system
Industry: Biotech

Beyond the preview

Go deeper on Vaxcel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxcel.

Explore the full profile